Summary Two clinical studies were undertaken to study the toxicity profile and effects of interleukin-3 (rhIL-3) on chemotherapy-induced myelosuppression.
Increasing the dose of certain cytostatic drugs may improve treatment results in some chemosensitive tumours (Juttner et al., 1989; Dunphy et al., 1990; de Vita et al., 1989) . In patients with ovarian cancer, cisplatin and carboplatin demonstrated dose-related activity (Ozols et al., 1985; 1987) and in these patients both probability of response and survival are directly related to dose intensity of these compounds (Levin & Hryniuk, 1987; Kaye et al., 1992) . In small cell lung cancer (SCLC) the clinical outcome may also correlate with dose-intensity (Murray, 1987) . Thus, increasing dose intensity may improve the efficacy of chemotherapy in the treatment of ovarian cancer and SCLC. Unfortunately, the degree of dose escalation that may be achieved in practice is usually limited by toxicity. For carboplatin the dose limiting toxicity is myelosuppression, predominantly thrombocytopenia (Curt et al., 1983; Egorin et al., 1984; Harland et al., 1984) .
Shortening the duration and depth of chemotherapyinduced neutropenia and thrombocytopenia should reduce the incidence and severity of infections and bleeding complications. Use of haematopoietic growth factors may prove beneficial by reducing toxicity of chemotherapy. Granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage CSF (GM-CSF) have clearly reduced the depth and extent of neutrophil nadirs, and reduced the incidence of serious infection (Ohno et al., 1990; Crawford et al., 1991; de Vries et al., 1991) . Unfortunately, neither G-CSF nor GM-CSF could adequately ameliorate thrombocytopenia due to cytotoxic therapy and therefore may not permit significant dose escalation of drugs which are associated with thrombocytopenia.
Recombinant human interleukin-3 (rhIL-3) is a multilineage haemopoietin that promotes the growth and differentiation of multipotent progenitor cells and committed progenitor cells of the granulocyte/macrophage, eosinophil, basophil, megakaryocyte, and erythroid lineages (Leary et al., 1987; Saeland et al., 1989; Sonoda et al., 1988) . has been shown to be a potent inducer of megakaryocyte development and thrombopoiesis in vitro Lu et al., 1988) . Preclinical studies of rhIL-3 in animal models showed a modest and delayed increase in neutrophils, basophils, and eosinophils. Increases in reticulocyte counts and variable increases in platelet counts were also observed (Metcalf et al., 1986; Donahue et al., 1988; Wagemaker et al., 1990) .
Clinical experience with rhIL-3 is limited. Several studies with rhIL-3 have been reported, including studies in patients with advanced malignancies (Ganser et al., 1990a; Kurzrock et al., 1991) , myelodysplastic syndromes (Ganser et al., 1990c) , and aplastic anaemia (Ganser et al., 1990b) . Only a few studies have reported rhIL-3 administration in patients with chemotherapy-induced myelosuppression (Kurzrock et al., 1991; Biesma et al., 1992) . These studies indicated that rhIL-3 induced a multilineage response showing beneficial effects on platelet counts at various doses.
Before haematophoietic growth factors can achieve widespread use, it is essential to demonstrate their efficacy and safety when given in combination with different chemotherapeutic regimens and in different schedules of administration. We therefore conducted two phase I/II studies with rhIL-3 in patients with ovarian cancer and in patients with small cell undifferentiated tumours. In the former study the bone marrow was challenged with high doses of the myelosuppressive agent carboplatin, while a more conventional regimen was used in the second study. In this paper we present the clinical results of these studies.
Patients and methods

Patient selection
Patients were treated with chemotherapy plus rhIL-3 in two different protocols. Patients with ovarian carcinoma recurrent after previous platinum-based chemotherapy were included in the first study and patients with small cell undifferentiated tumours in the second study. Most of the small cell tumours originated in the lung and both patients with limited or extensive disease were entered into the study. All patients were less than 70 years of age, had a performance status of >60% (Karnofsky scale) and a life expectancy of >2 months. Patients with severe heart, lung, liver (serum bilirubin >25 jimol 1', SGOT of SGPT > 1. 25 or normal) or kidney impairment (creatinine clearance < 50 ml min-) were excluded, as were patients with active infection, evidence of central nervous system metastases or of other malignancies. Evidence of adequate bone marrow function (leucocyte count ) 3.5 x I091' and platelet count > 100 x 1091`) was required. All patients gave informed consent and the protocols were approved by the Ethical and Scientific review committees of the Netherlands Cancer Institute and the Free University Hospital.
Recombinant human Interleukin-3 Escherichia Coli derived nonglycosylated rhIL-3 (2-10 x 106 U mg-' protein) was provided by Sandoz (Basel, Switzerland) as a lyophilised powder in vials of 150 g and 300 ig. The drug was reconstituted with 1 ml sterile water prior to administration as a daily subcutaneous injection.
Study design and treatment (a) The ovarian carcinoma study Fifteen consecutive patients with histologically verified recurrent ovarian carcinoma were entered into this study and treated with 800 mg m-2 carboplatin every 4 weeks for a total of four cycles. Carboplatin (Bristol-Myers Squibb, Princeton, NJ, USA) dissolved in 500 ml 5% glucose, was infused over 60 min. Anti-emetic treatment consisted of ondansetron with metoclopramide. RhIL-3 was administered subcutaneously at 5.0 jig/kg/d from the second cycle onwards and effects of rhIL-3 were compared with the first cycle (control cycle). The patients were divided into three groups of five patients each. Group I was treated with rhIL-3 for 10 days, starting 24 h after carboplatin administration. Group II also received rhIL-3 for 10 days, but starting 48 h after carboplatin infusion. In group III rhIL-3 was administered for 14 days, starting 48 h after chemotherapy. Three patients received rhIL-3 in the first cycle and therefore these cycles were not considered as control cycles.
(b) The small cell undifferentiated tumour study Patients with small cell undifferentiated tumours were treated with carboplatin 350 mg m2 (Bristol-Myers Squibb) in a 30 min infusion in 500 ml 5% glucose on day 1, etoposide 100 mg m-2 (Bristol-Myers Squibb) as an infusion in 0.9% saline over 30 min on days 1 -3 and ifosfamide 5 g m 2 (Asta Medica, Frankfurt, Germany) with an equivalent dose of mesna (Asta Medica) in a 24 h infusion on day 1 in 2 litre 0.9% NaCl. This treatment was repeated at 4 weekly intervals for six cycles provided that the disease did not progress.
The first cycle of chemotherapy was given without growth factor. In the second cycle rhIL-3 was administered from days 5-14. The same dose of chemotherapy was given in cycle 1 and 2. Three groups of patients were treated with rhIL-3 at the following dose levels: 0.125, 5.0 and 7.5 ljg/kg/ d. The study was terminated because rhIL-3 was no longer supplied.
In both studies red blood cell transfusions were given when the haemoglobin level dropped below 6.0 mmol 1i, and platelet transfusions were administered at platelet counts <10 x 109 1' or when bleeding occurred. No prophylactic antibiotics were administered. Acetaminophen (max. 3 g/day) was given when headache occurred.
Clinical and laboratory monitoring
Complete haematological blood counts, including differential cell counts, were performed every 2-3 days. Biochemical analysis was carried out on a weekly basis and creatinine clearance was measured every cycle. Axillary temperature and subjective toxicity were recorded twice daily. Tumour response was evaluated after each cycle of chemotherapy, according to UICC criteria (Hayward et al., 1977) .
Toxicity was graded according to the Common Toxicity Criteria (CTC) (Wittes, 1989 
Results
Ovarian carcinoma study Patient characteristics Fifteen patients were entered on study. The median age was 53 years (range, 34-69 years) and the median performance status was 80% (range, 60-100%) (Karnofsky scale). Five patients had a late relapse (>1 year), three patients had an early relapse (<1 year) following first-line chemotherapy and seven patients were refractory to previous chemotherapy. All patients had received at least six cycles of platinum-based chemotherapy (median 6, range: 6-15 cycles). The median time from diagnosis was 28 months (range, 6-154 months) and from last chemotherapy 6 months (range 1-64 months). Creatinine clearance (mean ± s.d.) at entry was 75 ± 8.5 ml min-', 80 ± 10.7 ml min-', and 83 + 17.3 ml min-' in group I, II and III, respectively. No significant differences could be found between the three patient populations, particularly when factors that might influence haematopoietic recovery were considered, i.e. performance status, age and time since or extent of previous pretreatment.
Side effects RhIL-3 was administered in 31 cycles of carboplatin which were evaluable for toxicity (group I: 7, group II: 12, group III: 12). In these cycles, the most frequently observed rhIL-3-related side effects were low-grade fever (CTC grade I) and headache (CTC grade I-II) (Table I) , which usually responded to acetaminophen. Facial flushing and diffuse erythema were noticed in a majority of the cycles (19/31). These usually started 1 -6 h after rhIL-3 administration and were most pronounced during the first days of treatment. In two patients local infiltrates at the injection site were seen. Other minor side effects consisted of muscle or bone pain and chills.
Beside the myelosuppression, side effects observed in cycles without rhIL-3 (control cycles) consisted of malaise, headache and chemotherapy-related nausea and vomiting (CTC grade III and IV), which had stopped within a week of chemotherapy. In cycles with rhIL-3, nausea and vomiting were more pronounced and extended over a longer period of time. After day 7, patients with rhIL-3 still experienced episodes of nausea (14/31) usually accompanied by vomiting (11/31) ( Table I) . Together with the malaise, headache and fever, this meant that high dose carboplatin in combination with rhIL-3 was poorly tolerated.
In 5/15 patients rhIL-3 was stopped due to toxicity. This occurred three times in group I in the first cycle with rhIL-3 In group II, rhIL-3 administration was started 48 h instead of 24 h after carboplatin infusion. In view of the observed toxicity in group I, these patients were extensively hydrated pre-and post-carboplatin administration. In the remaining ten patients no further nephrotoxicity was observed. Creatinine clearance at entry to each cycle did not differ significantly among the three groups (Table II) . One patient experienced a 40% decrease in mean arterial blood pressure 12 h after the first rhIL-3 administration in the fourth cycle and subsequently rhIL-3 treated was stopped. Forty-eight hours after rhIL-3 administration blood pressure had returned to normal. No changes in blood pressure requiring therapy were observed in the other nine patients.
Haematological recovery A total of 27 cycles of rhIL-3 were completed in 12 patients. Eleven patients were evaluable for efficacy of rhIL-3, one patient was not evaluable because of dose reduction of carboplatin in cycle 2. Treatment with 800 mg m-2 carboplatin in cycle 1 induced severe myelosuppression in all patients (Table II No significant difference in neutrophil or platelet nadir or in duration of neutropenia and thrombocytopenia was observed between 10 days (group II) and 14 days (group III) of rhIL-3 administration. The data from these two groups have therefore been combined in Table II . Administration of rhIL-3 in the second cycle of chemotherapy significantly reduced both the neutrophil nadir and the duration of neutropenia. The median absolute neutrophil count nadir increased to 0.27 x 1091' (P <0.05) and duration of grade IV neutropenia ( < 0.5 x 109 I`) was shortened to a median of 3 days from a median of 9 days in cycle 1 (P<0.01) (Figure 1 and Table II ). No significant difference was found for the absolute neutrophil count on day 28 of cycle 2 compared with the same time in cycle 1. However, postponement of chemotherapy by 1 or 2 weeks because of leucopenia (<3.5 x 1091-') occurred in 4/10 patients after the second cycle (with rhIL-3), as compared with postponement after the first cycle in 8/11 patients (without rhIL-3).
The platelet nadirs were not significantly different in cycles Pts. requiring platelet transfusion (%) Figure 1 Nadir of neutrophils and duration of neutropenia grade IV (<0.5 x 109 1-') after 10 or 14 days of rhIL-3 administration in cycle 2 and 3 of the ovarian carcinoma study.
1 and 2 ( Figure 2 and Table II (Table III) . Skin abnormalities developed in 4/11 cycles and consisted of local infiltration at the injection site (1 pt), facial flushing (2 pts) and urticaria (1 pt). In four patients a significant decrease in blood pressure was noticed 1-24 h after rhIL-3 administration, however, this effect was not dose related. In none of these patients rhIL-3 treatment had to be discontinued.
Haematological recovery The treatment with carboplatin 350 mg m2 (day 1), ifosfamide 5 g m2 (day 1) and etoposide 100 mg m-2 (day 1-3) produced severe myelosuppression in the first cycle (Table IV (Table IV) .
No effects were observed on basophils, monocytes, lym- Tumour response Twelve patients participated in the study and all patients had measurable disease. Five patients received all six cycles of chemotherapy, three patients five cycles and three patients received only three cycles due to early progression. One patient received only one cycle because of a severe sepsis encountered in the first cycle.
Of 11 evaluable patients, five patients had a complete response, another three patients had a partial response and three patients had stable disease. The overall response rate in these 11 patients was 73% (95% confidence interval, 40-93%). The median time to disease progression was 7 months (range, 4-10 months). aMedian. bRange.
Discussion
We conducted two clinical studies to assess the efficacy and toxicity of recombinant human interleukin-3 (rhIL-3) in ameliorating chemotherapy-induced myelosuppression. Both carboplatin-containing regimens produced a marked degree of myelosuppression. In the ovarian carcinoma study, administration of rhIL-3 in the second cycle of chemotherapy significantly reduced the neutrophil nadir and shortened the duration of grade IV neutropenia, a threshold known to be critical in view of infective complications (Bodey et al., 1965) . In this study no effect was seen on the platelet nadir, but rhIL-3 significantly shortened the duration of the chemotherapy-induced thrombocytopenia and reduced the number of platelet transfusions required which reached clinically relevant levels. Despite the continued use of rhIL-3, a progressive and severe thrombocytopenia developed when repeated cycles of high-dose chemotherapy were administered. A prolongation of the rhIL-3 administration from 10 to 14 days did not influence the severity or duration of thrombocytopenia. A possible explanation for the failure of rhIL-3 to offer protection in the third cycle is cumulative myelotoxicity of high dose carboplatin in conjunction with heavy pretreatment. It is known that carboplatin is a stem cell toxin (Schmalbach & Borch, 1989; Teicher et al., 1989) and that haematopoietic growth factors are less effective in patients with reduced bone marrow reserve . Other explanations could be induction of negative feedback loops by natural inhibitors of the haematopoiesis (Graham et al., 1990; Keller et al., 1990) and generation of rhIL-3-neutralising antibodies. However, antibodies against rhIL-3 have not been identified in over 500 samples from patients treated with rhIL-3 (personal communication, T.C. Jones, Sandoz Pharma Ltd, Basle).
In the small cell tumour study administration of rhIL-3 in the second cycle of chemotherapy did not protect against myelotoxicity. The difference in the effect of rhIL-3 in these two studies requires explanation. RhIL-3 stimulates haematopoiesis at the level of the multipotent and lineagecommitted progenitor cells, resulting in a gradual appearance (after 5 -10 days) of neutrophils, platelets and reticulocytes in the peripheral blood (Leary et al., 1987; Messner et al., 1987; Sonoda et al., 1988) . In the study of Ganser et al. in patients with normal haematopoiesis elevation of neutrophil and platelet counts was observed 1 week after the start of rhIL-3 treatment and maximum counts were reached between days 15 and 20 (Ganser et al., 1990a) . In the small cell tumour study, where rhIL-3 was begun 6 days after the first day of chemotherapy, the median time between the start of rhIL-3 treatment and occurrence of the nadir was 6 days (range, 5-7 days) and for the ovarian carcinoma study, where rhIL-3 began within 48 h of chemotherapy, this was 15 days (range, 13-17 days). These data suggest that rhIL-3 can have an effect on chemotherapy-induced neutropenia and thrombocytopenia if there is sufficient time between the start of the rhIL-3 treatment and the occurrence of the nadir. It should be emphasised that efficacy of rhIL-3 remains to be evaluated in a double blind placebo controlled study.
Chemotherapy can mobilise CD34 positive progenitor cells into the peripheral blood (Richman et al., 1976; Reiffers et al., 1986; . RhIL-3 can expand the pool of circulating progenitors (Geissler et al., 1990; Brugger et al., 1992) ; an effect seen also with G-CSF and GM-CSF (Socinski et al., 1988; Duhrsen et al., 1988; Gianni et al., 1989) . In the ovarian carcinoma study, CD34 positive progenitor cells transiently circulated in the peripheral blood in the first cycle of chemotherapy, however, rhIL-3 did not enhance the recruitment of CD34 positive cells. In our study patients had been extensively pretreated, a factor known to be associated with poor mobilisation of progenitor cells . In addition, haematopoietic recovery after carboplatin chemotherapy is slow and this may mitigate against a rebound increase in progenitor cells and the mobilising effect of rhIL-3. Of particular interest is the rhIL-3 related toxicity observed in the two studies. In the small cell tumour study the observed toxicity in patients treated with rhIL-3 up to a dose of 7.5 jig kg/d was similar to that reported by others (Ganser et al., 1990a; Kurzrock et al., 1991; Biesma et al., 1992) . In the ovarian carcinoma study, the adverse events considered to be related to rhIL-3 were more pronounced and severe toxicity was encountered. The side effects, such as headache, fever, and malaise, may be related to high dose carboplatin but administration of rhIL-3 clearly worsened these chemotherapy associated toxicities. These side effects together with the prolongation of nausea and vomiting meant that the combination of high dose carboplatin and rhIL-3 was poorly tolerated.
The difference in toxicity between the two studies, particularly hypotension, nephrotoxicity and malaise, is striking. The toxicity was most marked when rhIL-3 was administered 24 h after carboplatin infusion (group I) and in this group rhIL-3 treatment was stopped due to nephrotoxicity in two patients and severe malaise in one other. No severe nephrotoxicity has been encountered in our earlier studies, in which patients were treated with 800 mg m-2 carboplatin alone or in combination with GM-CSF (Ten Bokkel Huinink et al., 1992) . In published series, the incidence of renal side effects with carboplatin has varied from 0% to 35% (Calvert et al., 1982; Adams et al., 1989; Mangioni et al., 1989) . Acute renal failure attributable to this drug is rare and only a few cases of renal failure have been reported in the literature (Curt et al., 1983; Lee et al., 1988; McDonald et al., 1991) . Gore et al. noted decrements in glomerular filtration rate at all dose ranges when treating patients with doses of carboplatin of 800 mg m-2 or higher (Gore et al., 1987) . The observed nephrotoxicity in our study could be attributable to carboplatin and was likely aggravated by the rhIL-3-induced hypotension.
A significant decrease in blood pressure was noticed 1-24 h after rhIL-3 administration in both studies (ovarian carcinoma study: 9/31 cycles, small cell tumour study: 4/11 cycles). In one patient, treated with 0.125 1tg kg-' or rhIL-3, significant drop in blood pressure occurred, indicating that even a low dose of rhIL-3 could be associated with hypotension.
In the ovarian cancer study, acute toxicity with hypotension and renal dysfunction could be reduced by hyperhydration and delaying beginning rhIL-3-treatment to 48 h after chemotherapy. Toxicity was less in the small cell study. These patients, which were treated with a different chemotherapeutic regimen, had received no prior chemotherapy, the creatinine clearance was higher, the dose of carboplatin was lower, and rhIL-3 was started later in the chemotherapy cycle. These factors could explain the differences in observed toxicity between the two studies. However, the high dose of carboplatin is likely the most important cause of the excessive toxicity observed with the combination in the ovarian carcinoma study.
In conclusion, this report demonstrates that rhIL-3 has the capacity to ameliorate chemotherapy-induced neutropenia as well as thrombocytopenia. As used in the studies here, however, rhIL-3 could not prevent cumulative platelet toxicity due to multiple doses of high dose carboplatin. The haematological effects and the toxicity are dependent on the chosen chemotherapeutic regimen, schedule, dose and duration of rhIL-3 treatment. The combination of high dose carboplatin-containing regimens and rhIL-3 may cause severe toxicity, such as hypotension and nephrotoxicity, when the scheduling allows overlapping of the toxic effects of both agents.
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